The impact of metformin on survival in diabetic endometrial cancer patients: a retrospective population-based analysis

被引：2
作者：
Drevinskaite, Mingaile [1 ]
Kaceniene, Auguste [1 ]
Linkeviciute-Ulinskiene, Donata [2 ]
Smailyte, Giedre [1 ,3 ]
机构：
[1] NCI, Lab Canc Epidemiol, P Baublio 3B, LT-08406 Vilnius, Lithuania
[2] Vasteras Hosp, Med Clin, Vasteras, Sweden
[3] Vilnius Univ, Inst Hlth Sci, Fac Med, Dept Publ Hlth, Vilnius, Lithuania
来源：
JOURNAL OF DIABETES AND METABOLIC DISORDERS | 2024年 / 23卷 / 01期
基金：
英国医学研究理事会;
关键词：
Endometrial cancer; Type 2 Diabetes Mellitus; Metformin; Overall survival; Cancer-specific survival; RISK; METAANALYSIS; CARCINOMA; MORTALITY; MELLITUS;
D O I：
10.1007/s40200-023-01358-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PurposeThe aim of our study was to assess overall survival and cancer-specific survival in endometrial cancer patients with type 2 diabetes mellitus (T2DM) using metformin.MethodsPatients with endometrial cancer and T2DM during 2000-2012 period were identified from the Lithuanian Cancer Registry and the National Health Insurance Fund database. Cancer-specific and overall survival were primary outcomes.ResultsIn our study we included 6287 women with endometrial cancer out of whom 664 were diagnosed with T2DM (598 metformin users and 66 never users). During follow-up (mean follow-up time was 8.97 years), no differences in risk of endometrial cancer specific mortality was observed in diabetic patients treated with metformin (Hazard Ratio (HR) 0.87, 95% Confidence Interval (CI) 0.70-1.07). Overall mortality in the diabetic metformin ever users' group was significantly higher compared with the non-diabetic endometrial cancer women (HR 1.17, 95% CI 1.03-1.32) and in the group of metformin never users with T2DM (HR 1.42, 95% CI 1.07-1.87).ConclusionOur study results suggest no beneficial impact on overall and cancer-specific survival in endometrial cancer patients who were treated with metformin as part of their diabetes treatment.
引用
收藏
页码：909 / 916
页数：8
相关论文
共 31 条
[1]   The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts [J].
Al Hilli, Mariam M. ;
Bakkum-Gamez, Jamie N. ;
Mariani, Andrea ;
Cliby, William A. ;
Mc Gree, Michaela E. ;
Weaver, Amy L. ;
Dowdy, Sean C. ;
Podratz, Karl C. .
GYNECOLOGIC ONCOLOGY, 2016, 140 (02) :270-276
[2]   Endometrial cancer [J].
Amant, F ;
Moerman, P ;
Neven, P ;
Timmerman, D ;
Van Limbergen, E ;
Vergote, I .
LANCET, 2005, 366 (9484) :491-505
[3]   Cause-specific mortality in endometrioid endometrial cancer patients with type 2 diabetes using metformin or other types of antidiabetic medication [J].
Arima, R. ;
Hautakoski, A. ;
Marttila, M. ;
Arffman, M. ;
Sund, R. ;
Ilanne-Parikka, P. ;
Kangaskokko, J. ;
Hinkula, M. ;
Puistola, U. ;
Laara, E. .
GYNECOLOGIC ONCOLOGY, 2017, 147 (03) :678-683
[4]   Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory [J].
Arnold, Melina ;
Karim-Kos, Henrike E. ;
Coebergh, Jan Willem ;
Byrnes, Graham ;
Antilla, Ahti ;
Ferlay, Jacques ;
Renehan, Andrew G. ;
Forman, David ;
Soerjomataram, Isabelle .
EUROPEAN JOURNAL OF CANCER, 2015, 51 (09) :1164-1187
[5]   2 PATHOGENETIC TYPES OF ENDOMETRIAL CARCINOMA [J].
BOKHMAN, JV .
GYNECOLOGIC ONCOLOGY, 1983, 15 (01) :10-17
[6]  
Creasman W T, 2006, Int J Gynaecol Obstet, V95 Suppl 1, pS105
[7]   Understanding the benefit of metformin use in cancer treatment [J].
Dowling, Ryan J. O. ;
Goodwin, Pamela J. ;
Stambolic, Vuk .
BMC MEDICINE, 2011, 9
[8]   Epidemiology of Endometrial Carcinoma: Etiologic Importance of Hormonal and Metabolic Influences [J].
Felix, Ashley S. ;
Yang, Hannah P. ;
Bell, Daphne W. ;
Sherman, Mark E. .
MOLECULAR GENETICS OF ENDOMETRIAL CARCINOMA, 2017, 943 :3-46
[9]   Metformin and cancer-specific survival among breast, colorectal, or endometrial cancer patients: A nationwide data linkage study [J].
Feng, Jia-Li ;
Qin, Xiwen .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 175
[10]   Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods [J].
Ferlay, J. ;
Colombet, M. ;
Soerjomataram, I. ;
Mathers, C. ;
Parkin, D. M. ;
Pineros, M. ;
Znaor, A. ;
Bray, F. .
INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (08) :1941-1953
1234